Home » Stocks » PBLA

Panbela Therapeutics, Inc. (PBLA)

Stock Price: $4.04 USD -0.02 (-0.49%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 38.43M
Revenue (ttm) n/a
Net Income (ttm) -4.86M
Shares Out 7.89M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.04
Previous Close $4.06
Change ($) -0.02
Change (%) -0.49%
Day's Open 4.12
Day's Range 3.90 - 4.20
Day's Volume 55,192
52-Week Range 2.49 - 4.50

News

GlobeNewsWire - 1 month ago

MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients w...

Other stocks mentioned: SNBP

About PBLA

Panbela Therapeutics, a clinical-stage biopharmaceutical company, engages in developing therapeutics treatment for unmet medical needs. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics Inc. in December 2020. Panbela Therapeutics Inc. was founded i... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Michael Cullen
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
PBLA
Full Company Profile

Financial Performance

Financial Statements